|
|
|
|
|
|
Therapy Antibiotics are the only causal therapy for pneumonia. The antibiotics that are used depend on the nature of the pneumonia and the immune status of the patient. Amoxicillin is used as first-line therapy in the vast majority of community patients, sometimes with added clarithromycin. In North America, where the atypical forms of community acquired pneumonia are becoming more common, clarithromycin, azithromycin, and the fluoroquinolones have displaced the penicillin-derived drugs as first line therapy. In hospitalized patients and immune deficient patients, local guidelines generally determine which combination of (generally intravenous) antibiotics is used. Prognosis and mortality The clinical state of the patient at time of presentation is a strong predictor of the clinical course. Hopes that TB could be completely eliminated have been dashed since the rise of drug-resistant strains in the 1980s. For example, TB cases in Britain, numbering around 50,000 in 1955, had fallen to around 5,500 in 1987, but in 2001 there were over 7,000 confirmed cases. Due to the elimination of public health facilities in New York in the 1970s, there was a resurgence in the 1980s. The number of those failing to complete their course of drugs was very high. NY had to cope with more than 20,000 'unnecessary' TB-patients with many multi-drug resistant strains (i.e., resistant to, at least, both Rifampin and Isoniazid). The resurgence of tuberculosis resulted in the declaration of a global health emergency by the World Health Organization in 1993. In 2003, by disabling a set of genes, researchers accidentally created a more lethal and rapidly reproducing strain of tuberculosis bacteria. Click on following items to see more information: Acinetobacter, Antibacterial, Antibiotic, Antibiotic, Antibacterial, Bacilli, Bacterium, Bacterium, Antibacterial, Phages, Biofilm, Campylobacter, Cell culture, Ciprofloxacin, Cryptococcus, E. coli, E. coli, E. coli, E. coli, E. coli, E. coli, Erythromycin, Functional genomics, Yeast, Haemophilus, Kluyveromyces, Meningococci, Bacterial, Microflora, Multidrug resistance, Pathogenic bacteria, Prokaryote, P. aeruginosa, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Salmonella, Salmonella, Staphylococci, Staphylococci, Streptococcus, Streptomycin, Vibrio The Hydrogenophilaceae are a small family of Proteobacteria, with two genera. Hydrogenophilus are thermophilic, growing around 50°C, and obtain their energy from oxidizing hydrogen. The genus Thiobacillus, redefined to include only those species included among the beta proteobacteria, is also included here. Other members of Thiobacillus were transfred to Acidithiobacillus, Halothiobacillus and Thermithiobacillus, now placed in other families. The Enterobacteriaceae are a large family of bacteria, including many of the more familiar pathogens, such as Salmonella and Escherichia coli. Genetic studies place them among the Proteobacteria, and they are given their own order (Enterobacteriales), though this is sometimes taken to include some related environmental samples. Not all contaminants are readily treated through the use of bioremediation; for example, heavy metals such as cadmium and lead are not readily absorbed or captured by organisms. The integration of metals such as mercury into the food chain may make things worse as organisms bioaccumulate these metals. However, there are a number of advantages to bioremediation, which may be employed in areas which cannot be reached easily without excavation. For example, hydrocarbon spills (or more specific: gasoline) may contaminate groundwater well below the surface of the ground; injecting the right organisms, in conjunction with oxygen-forming compounds, may significantly reduce concentrations after a period of time. This is much less expensive than excavation followed by burial elsewhere or incineration, and reduces or eliminates the need for pumping and treatment, which is a common practice at sites where hydrocarbons have contaminated groundwater.
|
© 2005
Transgalactic Ltd (manufacturer of Bioscreen C software) |
Privacy Statement | P.O. Box
1393, 00101 Helsinki, Finland,
Last modified: May 25, 2005
| ||||||
